Antisense Therapeutics up on U.S. FDA submission for muscular dystrophy drug

Percheron Therapeutics

09/12/2021 04:50

** Shares of biotech co  ANP.AX  rise as much as 8.3% to
A$0.195, on track for sharpest single-day pct gain since Nov 15
    ** Says it submitted the protocol synopsis for a nine-month
chronic monkey toxicology study to the U.S. Food and Drug
Administration (FDA) to support dosing of patients with ATL1102
beyond six months for Duchenne Muscular Dystrophy (DMD)
 urn:newsml:reuters.com:*:nASX59B3MW
    ** ATL1102 is a drug being developed by co to treat DMD, a
genetic disorder characterized by progressive muscle
degeneration 
    ** Adds that co could receive a rare paediatric disease
priority review voucher from FDA if the European trial for
ATL1102 is successful before Sept 30, 2026
    ** Stock gains after two days of trading halt, prior to
which it fell for four consecutive sessions 
    ** Stock up 38.5% this year, as of last close

 (Reporting by Roushni Nair in Bangalore)
 ((Roushni.Nair@thomsonreuters.com))